StudyLancet review: cannabinoids in chronic non-cancer pain — updated evidence synthesisRegulatoryGermany: BfArM publishes updated guidance on medicinal cannabis prescribingStudyNEJM: CBD adjunctive therapy in treatment-resistant epilepsy — long-term follow-upRegulatoryTGA Australia releases revised Special Access Scheme statisticsBusinessTilray and Aphria file expanded EU-GMP medical cannabis distribution agreementsRegulatoryUK MHRA consults on unlicensed cannabis-based medicinal products frameworkStudyJAMA: cannabinoids in chemotherapy-induced nausea — systematic review updateBusinessCanopy Growth restructures European operations amid German market expansionRegulatorySwissmedic authorises additional medicinal cannabis product classificationsStudyIACM publishes 2026 international consensus on cannabinoid dosing in palliative careStudyLancet review: cannabinoids in chronic non-cancer pain — updated evidence synthesisRegulatoryGermany: BfArM publishes updated guidance on medicinal cannabis prescribingStudyNEJM: CBD adjunctive therapy in treatment-resistant epilepsy — long-term follow-upRegulatoryTGA Australia releases revised Special Access Scheme statisticsBusinessTilray and Aphria file expanded EU-GMP medical cannabis distribution agreementsRegulatoryUK MHRA consults on unlicensed cannabis-based medicinal products frameworkStudyJAMA: cannabinoids in chemotherapy-induced nausea — systematic review updateBusinessCanopy Growth restructures European operations amid German market expansionRegulatorySwissmedic authorises additional medicinal cannabis product classificationsStudyIACM publishes 2026 international consensus on cannabinoid dosing in palliative care
About

Independent international education for cannabinoid medicine.

The Institute for Cannabinoid Therapy is an independent educational organisation dedicated to advancing the safe and responsible practice of cannabinoid therapeutics through rigorous professional education.

Mission

To advance the international education of healthcare professionals in the science and clinical practice of cannabinoid medicine.

Vision

A global community of practitioners equipped to make evidence-based, responsible and safe decisions in cannabinoid therapeutics.

Educational philosophy

Rigorous, evidence-based curriculum authored by practising clinicians and scientists, delivered with editorial independence.

Scientific integrity

Faculty selection, curriculum development and regulatory reviews are grounded in transparent, peer-reviewed practice.

International collaboration

Faculty from multiple jurisdictions ensure a genuinely comparative and global perspective.

Educational independence

Non-commercial curriculum, free of industry influence, funded through education and membership.